Trinity Biotech Q4 EPS $(0.72) Up From $(1.33) YoY, Sales $13.43M Miss $15.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech reported a Q4 EPS of $(0.72), improving from $(1.33) YoY, but missed sales estimates with $13.43M against the expected $15.00M. This represents a 25.55% decrease in sales compared to the same period last year.
April 04, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Trinity Biotech's Q4 earnings show an improvement in EPS but a significant miss in sales estimates and a decrease in sales YoY.
The improvement in EPS indicates cost management or operational efficiency, which could be seen positively. However, the miss in sales estimates and a significant year-over-year decrease in sales are likely to be viewed negatively by investors, potentially leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100